Authorized Generic of Tekturna Now Available

Da Hee Han, PharmD
|
1-in-3 men have some form of cardiovascular disease, according to the American Heart Association. An estimated 2.8 million men experience stroke each year and hypertension is common in younger men. Routine check-ups are important to monitor heart health.
1-in-3 men have some form of cardiovascular disease, according to the American Heart Association. An estimated 2.8 million men experience stroke each year and hypertension is common in younger men. Routine check-ups are important to monitor heart health.
PDL BioPharma has announced the availability of an authorized generic version of Tekturna (aliskiren hemifumarate; Noden Pharma).

PDL BioPharma has announced the availability of an authorized generic version of Tekturna (aliskiren hemifumarate; Noden Pharma).

Tekturna, a direct renin inhibitor, is indicated for the treatment of hypertension in patients aged 6 years and older. It works by decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to angiotensin I. During treatment, the effect of increased renin levels is blocked so that PRA, angiotensin I, and angiotensin II are all reduced, whether aliskiren is used as monotherapy or in combination with other antihypertensive agents.

Related Articles

Aliskiren hemifumarate tablets will be made available by Prasco, LLC in 150mg and 300mg strengths. Noden will continue to manufacture the brand products Tekturna and Tekturna HCT (aliskiren and hydrochlorothiazide).

For more information visit PDL.com.

Related Content

  • Latest News Your top articles for Tuesday

  • Haymarket Medical NetworkTop Picks

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More